Sana Biotechnology (SANA) Price & Analysis

Compare

835 Followers

SANA Stock Chart & Stats

$4.58

$3.38(204.85%)

At close: Jan 08 4:00 PM EST

$4.58

$3.38(204.85%)

Day’s Range― - ―

52-Week Range$1.26 - $6.55

Previous CloseN/A

Volume118.31M

Average Volume (3M)3.88M

Market Cap

$1.24B

Enterprise Value$849.74M

Total Cash (Recent Filing)$153.05M

Total Debt (Recent Filing)$89.74M

Price to Earnings (P/E)―

Beta1.23

Next Earnings

Mar 24, 2026

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.16

Shares Outstanding266,366,120

10 Day Avg. Volume2,269,979

30 Day Avg. Volume3,882,970

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)1.50

Price to Sales (P/S)0.00

P/FCF Ratio-1.47

Enterprise Value/Market Cap0.68

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-4.76

Forecast

1Y Price Target

$8.00

Price Target Upside74.67% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-0.56

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Proof Of ConceptSix-month UP421 data showing islet cell survival and function without immunosuppression provides tangible proof of concept for the HIP platform and supports differentiation in Type 1 diabetes therapy development.

Pipeline PrioritizationDecision to suspend allogeneic CAR-T programs and concentrate resources on SC451 and in vivo SG293 signals strategic focus on higher-value assets and may improve development efficiency for lead programs.

Regulatory SupportFDA INTERACT meeting clarity on the GMP master cell bank and nonclinical testing plan, combined with a Commissioner's National Priority Voucher for T1D, strengthens the case for an accelerated regulatory path and highlights regulatory prioritization of new T1D modalities.

Bears Say

Financial PositionA reported loss of $42 million along with a pro forma cash balance of $170 million raises questions about funding runway and increases the likelihood of future financing or strategic partnerships to support ongoing development.

Program DiscontinuationsDiscontinuation of SC291 and SC262 reflects pipeline attrition and indicates that some early-stage programs will not contribute near-term value, potentially reducing future upside from those assets.

Sana Biotechnology News

Sana Biotechnology price target raised to $7 from $6 at BofA

BofA raised the firm’s price target on Sana Biotechnology (SANA) to $7 from $6 and keeps a Buy...

12d ago

SANA

Sana Biotechnology Highlights Diabetes Cell Therapy Advances at Conference

Sana Biotechnology ( ($SANA) ) has issued an update. At the 44th Annual J.P. Morgan Healthcare Conference on...

4d ago

SANA

Sana Biotechnology announces publication of in vivo gene editing

Sana Biotechnology (SANA) announced that Nature Biotechnology has published a journal article titled “In vivo gene editing of...

1M ago

SANA

Sana Biotechnology’s Strategic Focus on T1D Therapies Justifies Buy Rating

H.C. Wainwright analyst Emily Bodnar reiterated a Buy rating on Sana Biotechnology today and set a price target...

2M ago

SANA

Sana Biotechnology Reports Reduced Losses and Strong Liquidity

Sana Biotechnology, Inc. ( ($SANA) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

SANA

Sana Biotechnology’s Strategic Shift and Financial Positioning Justify Buy Rating

TD Cowen analyst Marc Frahm has maintained their bullish stance on SANA stock, giving a Buy rating on...

2M ago

SANA

Sana Biotechnology reports Q3 EPS (16c), consensus (19c)

“Given our recent progress and the potentially transformative impact with SC451 in type 1 diabetes, as well as...

2M ago

SANA

Sana Biotechnology options imply 17.5% move in share price post-earnings

Pre-earnings options volume in Sana Biotechnology (SANA) is normal with calls leading puts 27:1. Implied volatility suggests the...

2M ago

SANA

Sana Biotechnology price target raised to $8 from $5 at Citizens JMP

Citizens JMP raised the firm’s price target on Sana Biotechnology (SANA) to $8 from $5 and keeps an...

3M ago

SANA

Sana Biotechnology Advances CAR-T Therapy with SC262 in Non-Hodgkin’s Lymphoma Study

Sana Biotechnology, Inc. (($SANA)) announced an update on their ongoing clinical study. Study Overview: Sana Biotechnology, Inc. is...

3M ago

SANA

Sana Biotechnology’s SC291 Study: A Promising Step in Autoimmune Disease Treatment

Sana Biotechnology, Inc. (($SANA)) announced an update on their ongoing clinical study. Study Overview: Sana Biotechnology, Inc. is...

3M ago

SANA

Sana Biotechnology strength attributed to EMJ Capital long call

Shares of Sana Biotechnology (SANA) are up $1.28, or 29% to $5.73 in afternoon trading after EMJ Capital’s...

3M ago

SANA

Wedbush bullish on Sana Biotechnology, initiates with an Outperform

As previously reported, Wedbush initiated coverage of Sana Biotechnology (SANA) with an Outperform rating and $5 price target...

4M ago

SANA

Sana Biotechnology initiated with an Outperform at Wedbush

Wedbush initiated coverage of Sana Biotechnology (SANA) with an Outperform rating and $5 price target Published first on...

4M ago

SANA

SANA FAQ

What was Sana Biotechnology’s price range in the past 12 months?

Sana Biotechnology lowest stock price was $1.26 and its highest was $6.55 in the past 12 months.

What is Sana Biotechnology’s market cap?

Sana Biotechnology’s market cap is $1.24B.

When is Sana Biotechnology’s upcoming earnings report date?

Sana Biotechnology’s upcoming earnings report date is Mar 24, 2026 which is in 65 days.

How were Sana Biotechnology’s earnings last quarter?

Sana Biotechnology released its earnings results on Nov 06, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.189 by $0.029.

Is Sana Biotechnology overvalued?

According to Wall Street analysts Sana Biotechnology’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sana Biotechnology pay dividends?

Sana Biotechnology does not currently pay dividends.

What is Sana Biotechnology’s EPS estimate?

Sana Biotechnology’s EPS estimate is -0.14.

How many shares outstanding does Sana Biotechnology have?

Sana Biotechnology has 266,366,120 shares outstanding.

What happened to Sana Biotechnology’s price movement after its last earnings report?

Sana Biotechnology reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.189. Following the earnings report the stock price went up 0.988%.

Which hedge fund is a major shareholder of Sana Biotechnology?

Currently, no hedge funds are holding shares in SANA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Sana Biotechnology Stock Smart Score

Neutral

Fundamentals

Return on Equity

-96.11%

Trailing 12-Months

Asset Growth

-22.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sana Biotechnology

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Sana Biotechnology (SANA) Earnings & Revenues

Historic Earnings Reports

SANA Stock 12 Month Forecast

Average Price Target

$8.00

▲(74.67% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","5":"$5","10":"$10","2.5":"$2.5","7.5":"$7.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.5,5,7.5,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.07,4.44923076923077,4.828461538461538,5.207692307692308,5.586923076923077,5.966153846153846,6.345384615384615,6.724615384615385,7.103846153846154,7.483076923076923,7.862307692307692,8.241538461538461,8.62076923076923,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.07,4.372307692307692,4.674615384615385,4.976923076923077,5.27923076923077,5.581538461538462,5.883846153846154,6.186153846153847,6.4884615384615385,6.7907692307692304,7.093076923076923,7.395384615384615,7.697692307692307,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.07,4.295384615384616,4.520769230769231,4.746153846153846,4.9715384615384615,5.196923076923077,5.422307692307692,5.647692307692308,5.873076923076923,6.098461538461539,6.323846153846153,6.549230769230769,6.774615384615385,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.85,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.95,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.07,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >